Among them, four microRNAs (miR-940, -451a, -16-5p, -17-3p), specifically targeting molecules involved in pathway conferring anti-HER2 resistance of BC cells (SRC, PTEN, IGFR1), were used to predict sensitivity to trastuzumab. The gene discussed is ERBB2; the disease is breast cancer.